Treating Hematologic Malignancies During a Pandemic: Utilizing Telehealth and Digital Technology to Optimize Care

Binder, Adam; Handley, Nathan; Wilde, Lindsay; Palmisiano, Neil; López, Ana María

doi:10.3389/fonc.2020.01183

Cited by 24 publications

(16 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An increase in mHealth use is a likely scenario, since the use of smartphones is growing, with estimates indicating that 77.6% of Europeans own a smartphone [16]. In this context, health apps designed for patients with HMs could serve as additional tools for telemedicine, patient education and life coaching, medication adherence, communication, and social media connections [17][18][19].…”

Section: Introductionmentioning

confidence: 99%

Smartphone Apps for Patients With Hematologic Malignancies: Systematic Review and Evaluation of Content

Gutiérrez¹,

Ramallo²,

González³

et al. 2022

JMIR Mhealth Uhealth

View full text Add to dashboard Cite

Background Hematological malignancies (HMs) are a heterogeneous group of cancers representing a significant cause of morbidity and mortality. The chronification of HMs and the increasing use of smartphones may lead patients to seek their current unmet needs through mobile health apps. Objective The goal of this review was to identify and assess the quality of smartphone apps aimed at patients diagnosed with HMs. Methods A systematic search of apps that were aimed at patients diagnosed with HMs, accessed from a Spain IP address, and were available on the iOS (App Store) and Android (Google Play) platforms was conducted in November 2021. The search terms used were “hematology,” “blood cancer,” “leukemia,” “lymphoma,” and “myeloma” apps in English, Spanish, or both languages. The identified apps were downloaded and analyzed independently by 2 reviewers. Information about general app characteristics was collected. The Mobile Application Rating Scale (MARS) was used to assess quality. The resulting parameter of the analyses, the mean score of the apps, was compared by Student t test. Results Overall, 18 apps were identified; 7 were available on Android, 5 were available on iOS, and 6 were available on both platforms. All included apps were free; 3 were published in 2021, and among the apps published before 2021, only 6 were updated in 2021. Most (16/18, 89%) of the apps were aimed at patients with leukemia or lymphoma (16). The primary purposes of the apps were to provide general information about the condition (16/18, 89%) and monitor symptoms and clinical parameters (11/18, 61%). Health care professionals contributed to the development of 50% (9/18) of apps; 6 were owned and supported by scientific societies, and 3 were developed with the participation of health care professionals. The mean MARS score for the overall quality of the apps was 3.1 (SD 1.0). The engagement and aesthetics subscales were the lowest rated subscales, with only 44% (8/18) and 67% (12/18), respectively, of the apps obtaining acceptable scores. None of the included apps proved clinical efficacy through clinical trials in patients with HMs. Statistically significant differences were found in the MARS scores between operating systems (+1.0, P=.003) in favor of iOS apps. The participation of health care professionals in the development of the apps did not have a statistically significant impact on the MARS scores. Conclusions This systematic search and evaluation identified few acceptable quality mobile apps for patients with HMs. Current and future apps for patients with HMs should provide evidence-based valuable information, improve user engagement, incorporate functions according to patient preferences, and generate evidence regarding the efficacy of app use by patients with HMs.

show abstract

Section: Introductionmentioning

confidence: 99%

Smartphone Apps for Patients With Hematologic Malignancies: Systematic Review and Evaluation of Content

Gutiérrez¹,

Ramallo²,

González³

et al. 2022

JMIR Mhealth Uhealth

View full text Add to dashboard Cite

show abstract

“… 27 , 29 Significant predictors of low eHealth literacy often include low socioeconomic status, lack of education on how to use the Internet, and older age. 19 , 44 , 45 Rural area residents, those with less than a college degree, or older adults are likelier to decline to participate in web-based programs, influencing intervention participation rates. 44 To expand access to web-based interventions for people with low eHealth literacy, it is important to develop an online platform with a simple interface and easy operation.…”

Section: Discussionmentioning

confidence: 99%

“… 19 , 44 , 45 Rural area residents, those with less than a college degree, or older adults are likelier to decline to participate in web-based programs, influencing intervention participation rates. 44 To expand access to web-based interventions for people with low eHealth literacy, it is important to develop an online platform with a simple interface and easy operation. 19 , 34 In addition, developing strategies to enhance the target population's knowledge and skills in using online platforms may also be an essential function for research teams, to maximize the delivery of web-based supportive programs.…”

Section: Discussionmentioning

confidence: 99%

The application of eHealth in cancer survivorship care: A review of web-based dyadic interventions for post-treatment cancer survivors and caregivers

Chen

Gong

2022

Asia-Pacific Journal of Oncology Nursing

View full text Add to dashboard Cite

“…15 Such approaches serve to streamline the process by which patients access care. [15][16][17][18][19] It is important to note that efforts to streamline care will not resolve all opportunity costs associated with cancer care, and not all options to do so will be desirable or feasible for all patients. For example, telehealth may not be equally implemented for patients who are low income, underinsured, or otherwise vulnerable.…”

Section: Discussionmentioning

confidence: 99%

Development of the Oncology Opportunity Cost Assessment Tool: Item Generation and Content Validity Testing

Handley

Binder

Heyer

et al. 2022

JCO Oncology Practice

Self Cite

View full text Add to dashboard Cite

PURPOSE: The purpose of this study was to develop the Oncology Opportunity Cost Assessment Tool (OOCAT), a survey instrument to evaluate the opportunity costs patients experience when seeking medical oncology care. METHODS: Development of the OOCAT involved extensive patient engagement through both focus groups and interviews. First, the study team developed a list of opportunity cost concepts, which included patients' logistical and financial considerations related to seeking care. We conducted focus groups with patients to expand upon this list of concepts, and then developed a set of questions that incorporated all the concepts generated during the focus groups. To refine these questions, we next performed cognitive interviews with another set of patients to ensure content validity and clarity of instrument items, refining the OOCAT iteratively on the basis of feedback. RESULTS: We engaged 23 participants (17 patients and six caregivers) across four focus groups and 17 participants in cognitive interviews. Focus group participants generated 112 concepts, which resulted in an initial OOCAT with 16 questions. Cognitive interviews resulted in modification of 12 questions and addition of two questions (related to coordination of transportation and impact on home responsibilities). The final OOCAT consisted of 18 items examining time requirements for appointments, financial implications of traveling to appointments for the patient and the caregiver, and logistical and quality-of-life challenges associated with traveling for appointments. CONCLUSION: We developed the OOCAT, an instrument designed to evaluate patient-level opportunity costs of seeking medical oncology care. Further studies to validate the OOCAT are underway.

show abstract

Treating Hematologic Malignancies During a Pandemic: Utilizing Telehealth and Digital Technology to Optimize Care

Cited by 24 publications

References 47 publications

Smartphone Apps for Patients With Hematologic Malignancies: Systematic Review and Evaluation of Content

Smartphone Apps for Patients With Hematologic Malignancies: Systematic Review and Evaluation of Content

The application of eHealth in cancer survivorship care: A review of web-based dyadic interventions for post-treatment cancer survivors and caregivers

Development of the Oncology Opportunity Cost Assessment Tool: Item Generation and Content Validity Testing

Contact Info

Product

Resources

About